TY - JOUR T1 - Dual genome-wide CRISPR knockout and CRISPR activation screens identify common mechanisms that regulate the resistance to multiple ATR inhibitors JF - bioRxiv DO - 10.1101/2020.04.08.032854 SP - 2020.04.08.032854 AU - Emily M. Schleicher AU - Ashna Dhoonmoon AU - Kristen E. Clements AU - Lindsey M. Jackson AU - Coryn L. Stump AU - Claudia M. Nicolae AU - George-Lucian Moldovan Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/04/09/2020.04.08.032854.abstract N2 - The ataxia telangiectasia and Rad3-related (ATR) protein kinase is a key regulator of the cellular response to DNA damage. Due to increased amount of replication stress, cancer cells heavily rely on ATR to complete DNA replication and cell cycle progression. Thus, ATR inhibition is an emerging target in cancer therapy, with multiple ATR inhibitors currently undergoing clinical trials. Here, we describe dual genome-wide CRISPR knockout and CRISPR activation screens employed to comprehensively identify genes that regulate the cellular resistance to ATR inhibitors. Specifically, we investigated two different ATR inhibitors, namely VE822 and AZD6738, in both HeLa and MCF10A cells. We identified and validated multiple genes that alter the resistance to ATR inhibitors. Importantly, we show that the mechanisms of resistance employed by these genes are varied, and include restoring DNA replication tract progression, and prevention of ATR inhibitor-induced apoptosis. Our dual genome-wide screen findings pave the way for personalized medicine by identifying potential biomarkers for ATR inhibitor resistance.Competing Interest StatementThe authors have declared no competing interest. ER -